Molecular Basis and Clinical Application of Growth-Factor-Independent In Vitro Myeloid Colony Formation in Chronic Myelomonocytic Leukemia.
Adult
Aged
Aged, 80 and over
Animals
Cell Line, Tumor
Enhancer of Zeste Homolog 2 Protein
/ genetics
Female
GTP Phosphohydrolases
/ genetics
Gene Expression Regulation, Leukemic
Humans
Intercellular Signaling Peptides and Proteins
/ metabolism
Janus Kinase 2
/ genetics
Leukemia, Myelomonocytic, Chronic
/ genetics
Male
Membrane Proteins
/ genetics
Mice
Middle Aged
Mutation
Prognosis
Proto-Oncogene Proteins c-cbl
/ genetics
Tumor Stem Cell Assay
ras Proteins
/ genetics
AML
CFU-GM
CMML
NGS
in vitro cultures
prognosis
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
22 Aug 2020
22 Aug 2020
Historique:
received:
26
07
2020
revised:
20
08
2020
accepted:
21
08
2020
entrez:
27
8
2020
pubmed:
28
8
2020
medline:
10
4
2021
Statut:
epublish
Résumé
We have originally reported that colony-forming units granulocyte/macrophage (CFU-GM) formation is an in vitro feature of chronic myelomonocytic leukemia (CMML) and a strong predictor for short survival. Elucidation of the molecular basis underlying this in vitro phenomenon could be helpful to define molecular features that predict inferior outcome in patients. We studied the correlation between the mutational landscape and spontaneous colony formation in 164 samples from 125 CMML patients. As compared to wildtype samples, spontaneous in vitro CFU-GM formation was significantly increased in samples containing mutations in
Identifiants
pubmed: 32842710
pii: ijms21176057
doi: 10.3390/ijms21176057
pmc: PMC7504428
pii:
doi:
Substances chimiques
Intercellular Signaling Peptides and Proteins
0
Membrane Proteins
0
EZH2 protein, human
EC 2.1.1.43
Enhancer of Zeste Homolog 2 Protein
EC 2.1.1.43
Proto-Oncogene Proteins c-cbl
EC 2.3.2.27
JAK2 protein, human
EC 2.7.10.2
Janus Kinase 2
EC 2.7.10.2
GTP Phosphohydrolases
EC 3.6.1.-
NRAS protein, human
EC 3.6.1.-
ras Proteins
EC 3.6.5.2
CBL protein, human
EC 6.3.2.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Austrian Science Fund (FWF)
ID : F4704-B20
Organisme : Gesellschaft zur Erforschung der Biologie und Therapie von Tumorkrankheiten
ID : ABCMML-112015
Références
Wien Klin Wochenschr. 2003 Aug 14;115(13-14):537-46
pubmed: 13677271
Blood. 2007 May 1;109(9):3945-52
pubmed: 17192389
Int J Mol Sci. 2020 Apr 24;21(8):
pubmed: 32344757
Blood. 1989 Oct;74(5):1472-6
pubmed: 2676012
Wien Klin Wochenschr. 2019 Sep;131(17-18):410-418
pubmed: 31321531
Cell. 2000 Jan 7;100(1):57-70
pubmed: 10647931
Exp Hematol. 2002 Oct;30(10):1124-31
pubmed: 12384142
FASEB J. 2014 Aug;28(8):3540-51
pubmed: 24760752
Ann Hematol. 2004 Jan;83(1):9-13
pubmed: 13680175
Blood. 2004 Jun 1;103(11):4243-50
pubmed: 14982883
Aust J Exp Biol Med Sci. 1966 Jun;44(3):287-99
pubmed: 4164182
Leuk Res. 1988;12(5):373-7
pubmed: 3164085
J Exp Med. 1996 Oct 1;184(4):1377-84
pubmed: 8879210
Blood. 2010 Dec 23;116(26):5991-6002
pubmed: 20921338
Leukemia. 2016 Nov;30(11):2280-2281
pubmed: 27585952
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
J Mol Diagn. 2017 Jan;19(1):4-23
pubmed: 27993330
Blood. 2005 May 1;105(9):3737-42
pubmed: 15644411
Nouv Rev Fr Hematol. 1978;20(4):521-33
pubmed: 377223
Blood. 2011 Feb 10;117(6):2022-32
pubmed: 21163920
J Clin Oncol. 1991 Mar;9(3):381-8
pubmed: 1999707
N Engl J Med. 1993 Mar 4;328(9):614-9
pubmed: 8429853